Regular Training Increases sTWEAK and Its Decoy Receptor sCD163–Does Training Trigger the sTWEAK/sCD163-Axis to Induce an Anti-Inflammatory Effect?

Long-term physical activity leads to a significant increase in serum sRAGE levels: a sign of decreased AGE-mediated inflammation due to physical activity?

(2018) Michael Sponder et al.   HEART AND VESSELS

Physical Activity in the Prevention and Treatment of Coronary Artery Disease

(2018) Ephraim Bernhard Winzer et al.   Journal of the American Heart Association

Clinical significance of sCD163 and its possible role in asthma

(2017) Yue Zhi et al.   Molecular Medicine Reports

Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD

(2016) V. Fernandez-Laso et al.   Clinical Journal of the American Society of Nephrology

Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure

(2016) Katarzyna Ptaszynska-Kopczynska et al.   CYTOKINE

Long-term endurance training increases serum cathepsin S and decreases IL-6 and hsCRP levels

(2016) Michael Sponder et al.   JOURNAL OF SPORTS SCIENCES

Soluble CD163 masks fibronectin-binding protein A-mediated inflammatory activation ofStaphylococcus aureusinfected monocytes

(2013) Jessica Kneidl et al.   CELLULAR MICROBIOLOGY

Serum Levels of TWEAK and Scavenger Receptor CD163 in Type 1 Diabetes Mellitus: Relationship with Cardiovascular Risk Factors. A Case-Control Study

(2012) Gemma Llauradó et al.   PLoS One

Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease

(2011) Grazina Urbonaviciene et al.   ATHEROSCLEROSIS

Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension

(2011) Arthur Filusch et al.   Clinical Research in Cardiology

Soluble CD163

(2011) Holger J. Møller   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION

Peripheral Artery Disease Is Associated With a High CD163/TWEAK Plasma Ratio

(2010) Juan A. Moreno et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure

(2010) Bernhard Richter et al.   ATHEROSCLEROSIS

New immunological serum markers in bacteraemia: anti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis

(2010) S. Gaïni et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The CD163-expressing macrophages recognize and internalize TWEAK

(2009) Juan A. Moreno et al.   ATHEROSCLEROSIS

Circulating sTWEAK improves the prediction of coronary artery disease

(2009) Zorana Jelić-Ivanović et al.   CLINICAL BIOCHEMISTRY

Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure

(2009) Emmanuel Chorianopoulos et al.   EUROPEAN JOURNAL OF HEART FAILURE

Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease

(2007) Susan Kralisch et al.   ATHEROSCLEROSIS